Dipeptidyl-Peptidase 4 Inhibitors did not Improve Renal Endpoints in Advanced Diabetic Kidney Disease
- 1 December 2020
- journal article
- research article
- Published by Elsevier BV in Endocrine Practice
- Vol. 26 (12), 1486-1496
- https://doi.org/10.4158/ep-2020-0143
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Proteinuria should be used as a surrogate in CKDNature Reviews Nephrology, 2012
- Diabetic Nephropathy Amelioration by a Low-Dose Sitagliptin in an Animal Model of Type 2 Diabetes (Zucker Diabetic Fatty Rat)Experimental Diabetes Research, 2011
- Dipeptidyl Peptidase IV Inhibitor Attenuates Kidney Injury in Streptozotocin-Induced Diabetic RatsThe Journal of pharmacology and experimental therapeutics, 2011
- Sitagliptin reduces albuminuria in patients with type 2 diabetes [Rapid Communication]Endocrine Journal, 2011
- Interrelationship of dipeptidyl peptidase IV (DPP4) with the development of diabetes, dyslipidaemia and nephropathy: a streptozotocin-induced model using wild-type and DPP4-deficient ratsJournal of Endocrinology, 2008
- How Does Proteinuria Cause Progressive Renal Damage?Journal of the American Society of Nephrology, 2006
- Risk Factors for Renal Dysfunction in Type 2 DiabetesDiabetes, 2006
- Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64)Kidney International, 2003
- Involvement of dipeptidyl peptidase IV in an in vivo immune responseClinical and Experimental Immunology, 1992
- Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules?Kidney International, 1990